ResMed Inc. (RMD)

In the past six months, ResMed's stock experienced several notable events, including reaching an all-time high closing price of $293.03 on August 22, 2025. Since July 2025, the stock has generally been in a holding pattern, hovering around $254.41, and it underperformed the S&P 500's 11.3% gain during that period. On January 29, 2026, ResMed released its quarterly earnings results, reporting earnings per share of $2.81 and revenue of $1.42 billion, exceeding analyst expectations. Following these positive results, on February 7, 2026, ResMed's stock was upgraded to a "Buy" rating by Wall Street Zen, and the company announced a quarterly dividend of $0.60 per share. Earlier, on December 8, 2025, ResMed received FDA clearance for an AI-enabled device, "Smart Comfort," designed to personalize CPAP therapy settings. Insider trading activity in the last three months saw company insiders selling 21,594 shares valued at $5,403,495, and Wells Fargo modestly nudged its price target to $270 from $265 with an "equal weight" rating.

While specific seasonal fluctuations in demand for ResMed's products and services are not explicitly detailed, several factors contribute to a structurally growing market and influence demand. The increasing diagnosis of sleep apnea, coupled with aging populations and a rising prevalence of obesity, drives a consistent demand for ResMed's solutions. Furthermore, an enhanced focus on sleep health and sleep apnea by major pharmaceutical and consumer technology companies is expected to generate even greater demand for sleep health solutions. ResMed's strategic shift into diagnostics and SaaS, along with the integration of its myAir app with smartwatches, are also designed to drive and capture demand. Changes in healthcare policies and reimbursement rates can also significantly influence the demand for ResMed's products.

ResMed, Inc. is a global health technology company specializing in cloud-connected medical devices and software solutions for treating and managing sleep apnea, COPD, and other respiratory conditions. The company operates primarily within the Healthcare sector, specifically in the Medical Equipment & Services industry, focusing on Medical - Instruments & Supplies. ResMed's major products include CPAP and APAP devices, non-invasive and invasive ventilators, humidifiers, masks, nasal cannulas, and tubing. Additionally, ResMed offers SaaS solutions, such as healthcare management software and the AirView patient monitoring platform, designed to support out-of-hospital care. The company's devices, like the AirSense 11 platform, feature cloud connectivity for remote patient monitoring and therapy adjustments.

ResMed has a significant international presence, providing solutions in over 140 countries worldwide. Approximately two-thirds of its revenue is generated in the Americas, with the remaining balance coming from other regions, including Europe, Japan, and Australia.

ResMed maintains a strong brand reputation, driven by its mission to improve quality of life, reduce the impact of chronic disease, and lower healthcare costs in over 140 countries. The company is recognized for its commitment to pioneering innovative, life-changing health technologies. In fiscal year 2025, ResMed was recognized on several Forbes lists. ResMed responded to the impact of novel weight loss drugs by presenting epidemiological science and real-world evidence, demonstrating a positive response to sleep apnea therapy commencement for individuals prescribed both GLP-1 drugs and PAP therapy. The company's integration of its myAir app with Apple and Android smartwatches also contributes positively to its brand.

ResMed Inc. has a substantial institutional ownership base, with 1538 institutional owners and shareholders holding a total of 102,286,344 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Mutual Funds & ETFs hold 42.60% of shares outstanding, while other institutional investors hold 29.83%. Company insiders collectively own 0.65% of the company's stock.